中科生物(01237.HK)發行1.235億股新股將貸款資本化
格隆匯12月22日丨中科生物(01237.HK)發佈公告,2019年12月20日,公司與認購人A韓宏訂立認購協議I,據此,認購人A已有條件同意以資本化公司欠認購人A的債券I的部分金額及其應計利息741萬港元的方式按認購價0.12港元認購合共6176.67萬股新股。
同日,公司與認購人B韓金訂立認購協議II,據此,認購人B已有條件同意以資本化公司欠認購人B的債券I的部分金額及其應計利息741.2萬港元的方式按認購價0.12港元認購合共6176.67萬股新股。
認購股份總數佔公司現有已發行股本約20%,並佔本公司經配發及發行總認購股份擴大後已發行股本約16.67%。認購股份總數的認購價每股認購股份約0.12港元,相當於股份於2019年12月20日收市價每股0.12港元。
董事相信,藉貸款資本化將可減少公司的現金流出,將公司欠認購方債券的部分未償還款項轉換並資本化為股本符合公司的利益。董事會亦認為,貸款資本化將擴大本公司的資本基礎,並將降低集團的資產負債水平,從而增強集團的財務狀況。預期貸款資本化將不會對集團的營運及財務狀況造成任何重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.